INTRODUCTION There is no doubt that the race to develop a safe and effective vaccine against SARS-CoV-2 presents several challenges. Especially a vaccine the world awaits with bated breath. Russia now joins the rank of countries in this infamous vaccine race. On 11th August 2020, the Russian President announced that the Russian drug regulatory authorities had approved a COVID-19 vaccine developed by the Gamaleya Research Institute of Epidemiology, Moscow. The new adenovirus-based vaccine has been named “Sputnik V”. About the new vaccine According to published clinical trial details, the vaccine consists of two adenoviruses that express the coronavirus spike protein. It will be administered via intramuscular injection in two doses wherein the first dose is the viral strain Ad26 and the second dose is a ‘booster dose’ made of an Ad5 virus1. Behind the scenes of the Sputnik V vaccine Early-phase testing: On 18th June 2020, Russia commenced the first stage of clinical testing for this vaccine. It was a non-randomized, two-phased, early stage trial that tested the vaccine response in 76 healthy volunteers. The objective of this early phase study was to investigate the safety and tolerability of the vaccine in humans and assess its potential to trigger an immune response in vaccinated individuals1. As per the vaccine’s Russian-language registration certificate, all vaccinated participants successfully produced antibodies against the coronavirus spike protein. The vaccine also triggered the production of potent antibodies capable of neutralizing viral particles 2. Plans for Phase 3 trials At present, there are no published protocols formally detailing the design of late stage, large-scale Phase 3 trials for the Sputnik V vaccine. Phase 3 trials are imperative to further establishing the safety and efficacy of a vaccine before clinical use 2. CONCLUSION The challenges of developing a new COVID-19 vaccine are twofold. The first is developing an effective vaccine that is safe and harmless with a very low risk of instigating any rogue immune responses in recipients. The second challenge is doing so in a reasonable time frame considering the present pandemic 3. The world awaits more details regarding Phase 3 testing plans for this new vaccine. This will ascertain if it is safe to use in our global population. REFERENCES Clinicaltrials.gov. 2020. An Open Study Of The Safety, Tolerability And Immunogenicity Of The Drug "Gam-COVID-Vac" Vaccine Against COVID-19 - Full Text View - Clinicaltrials.Gov. [online] Available at: < target="_blank">https://clinicaltrials.gov/ct2/show/NCT04436471> [Accessed 12 August 2020]. Callaway, E., 2020. Russia’S Fast-Track Coronavirus Vaccine Draws Outrage Over Safety. [online] Nature.com. Available at: < target="_blank">https://www.nature.com/articles/d41586-020-02386-2> [Accessed 12 August 2020]. Peeples L. News Feature: Avoiding pitfalls in the pursuit of a COVID-19 vaccine. Proceedings of the National Academy of Sciences. 2020 Apr 14;117(15):8218-21.



Dr Prashant- I would love to reply to this post. Definitely-Sputnik V has won the race - but I would go into history of Russia which is relevant in this case . Russia was the first country to have its first astronaut in space - Yuri Gagarin . Russia was the first country to launch satellite named SPUTNIK, in space in 1957. But finally U.S.A won the race - as it was the first country who landed on moon in 1969 -namely Neil Armstrong . Now again naming - after its satellite SPUTNIK- launched the first vaccine when phase 3 trials are not yet started . For the time - being definitely we look towards Russia for the vaccine. But - I am confident- that U.S.A will sooner come with a vaccine only after all clinical trials are complete. American research is far more superior than other countries

I fully support the Russia they are very hard nut to crack and there dedication and commitment is second to non ,some communication mistake and to early to convey there research and few other factors not completed task but they did everything and for us they always support and stood weather it is peace and war like a true friend. I hope we will find solution to this red dragon sooner than later.

Thanks Dr Parveen Yograj

Too early to comment on a vaccine it self is under trial of 3rd phase Yes world need it earliest but not at a cost of adverse effects so india will have to wait still.

Valuable opinion

View 4 other replies

Informative Post

No,but a great hope as emerged

Informative post sir

Thank you doctor

Cases that would interest you